Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

The conference call may be accessed by dialing 877.419.6590 for domestic callers and 719.325.4872 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Q208 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is scheduled to present at the following investment and industry conferences through September 2008:

-- NewsMakers in the Biotech Industry Conference, September 4, 2008, New York, New York

-- UBS Global Life Sciences Conference, September 22-25, 2008, New York, New York

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include s
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 GliaCure, a privately-held ... therapies for neurological and neuropsychiatric disorders based on ... of Alzheimer,s patients in a Phase 1b clinical ... compound developed as a potential disease-modifying treatment. GliaCure,s ... in that it both promotes the clearance of ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)... China Cord Blood Corporation (NYSE: CO ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... Hong Kong listed company and a substantial ... (the "Agreement") to purchase the Company,s outstanding 7% senior ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... England, November 26 Sosei,Group Corporation ("Sosei"; TSE Mothers ... out-licensed its IP and Know How,relating to the RS(+) ... based pharma company, for the treatment and prophylaxis of,malaria. ... a highly efficacious anti-malarial drug that is approved in,its ...
... 25 Beckman Coulter, Inc. (NYSE: BEC ), ... automate, and innovate complex biomedical testing, announced today that Paul ... will present at the following conferences: , ... , , ...
... COLUMBUS, Ohio, Nov. 25 CAS REGISTRY, the world,s ... million organic and inorganic substances. CAS Registry Number(R),1073662-18-6 recently ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081125/CLTU095 ) ... http://www.newscom.com/cgi-bin/prnh/20070817/CLF008LOGO ) , ...
Cached Biology Technology:Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2Beckman Coulter to Present at Upcoming Healthcare Conferences 2CAS Registers 40 Millionth Substance in CAS REGISTRY(SM) 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... took the wraps off a new,line of sleek, powerful, ... Weighing just over 3 pounds, the VAIO Z model ... LCD,technology for scratch-resistant durability and 100 percent color,saturation., ... display,providing a 40 percent wider workspace than a standard ...
... The Ecological Society of America (ESA) will present societal ... ESA meeting in Milwaukee, Wisconsin on Monday, August 4, ... , Michael Rosenzweig of the University of Arizona is ... to a senior ecologist in recognition of an outstanding ...
... Society for Microbiology (ASM) Procter & Gamble Award ... to Edward F. DeLong, Professor, Massachusetts Institute of ... and development in applied and environmental microbiology. ... in the field of marine microbiology. His work ...
Cached Biology News:New Sony PC Delivers High Performance in Ultra-Portable Package 2New Sony PC Delivers High Performance in Ultra-Portable Package 3Ecological Society of America announces 2008 award recipients 2Ecological Society of America announces 2008 award recipients 3Ecological Society of America announces 2008 award recipients 4American Society for Microbiology honors Edward F. DeLong 2